In short
Clinical trials are investigating SGT-003 in people with Duchenne muscular dystrophy. These studies aim to assess safety, tolerability, and early signs of efficacy, including changes in microdystrophin protein levels. The current trial is a Phase 1/2 study in a target group of 60 participants.
Key points
- Clinical trials are studying SGT-003 in Duchenne muscular dystrophy. The main trial is a Phase 1/2 study that plans to enroll 60 participants. Researchers are testing a single intravenous dose and checking safety, tolerability, and early efficacy signals. The key outcomes are treatment-emergent adverse events through Day 360 and changes in microdystrophin protein levels at Day 90. The trial is currently authorised.
Trial overview
The available trial of SGT-003 is a study in people with Duchenne muscular dystrophy, which is a serious muscle disease that gets worse over time. The study is titled “A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy” and is listed as authorised.
This is an interventional study, which means researchers give the study treatment and then observe what happens. The trial plans to enroll 60 participants.
Study design and phase
The study is a Phase 1/2 trial. This early phase usually means the main goal is to learn about safety first, while also looking for early signs that the treatment may help.
Participants receive a single intravenous dose of SGT-003, meaning the treatment is given once through a vein. The source data does not provide more details about the visit schedule or other study procedures.
Who can participate
The target population is people with Duchenne muscular dystrophy. The source data does not list age limits, disease stage rules, or other detailed entry criteria.
Because the trial is in an early phase, participation is usually limited to a carefully selected group, but the exact rules are not provided in the source data.
What is being measured
The main safety measure is the incidence of treatment-emergent adverse events through Day 360. This means the researchers will count any unwanted health problems that start or worsen after treatment begins during the first year of follow-up.
The main efficacy measure is the change from baseline of microdystrophin protein levels at Day 90. “Baseline” means the starting point before treatment, and microdystrophin is the protein level the researchers are checking in muscle tissue.
The brief summary says the study also looks at microdystrophin expression in muscle biopsies, which are small samples of muscle taken for testing.
Why this trial matters
For people with Duchenne muscular dystrophy, early trials like this help researchers learn whether a new treatment can be studied safely in humans and whether it shows a biological effect. In this study, the biological effect is linked to microdystrophin levels in muscle tissue.
Because the trial is early and small, it is not meant to answer every question about long-term benefit. Instead, it is designed to give first important data on safety and early response in the target group.